Sanofi’s Dupilumab Study: A Closer Look at Long-term Treatment for Prurigo Nodularis

Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.

Sanofi is conducting a non-interventional study titled ‘Prospective, Non-interventional Observational Study to Characterize Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine.’ The study aims to evaluate the long-term effectiveness and safety of Dupilumab (Dupixent®) in treating moderate-to-severe prurigo nodularis (PN) in a real-world setting in Germany. This study is significant as PN remains understudied despite its increasing prevalence and burden.

The intervention being tested is Dupilumab, a drug administered via subcutaneous injection. It is intended to manage symptoms of PN, particularly the intense itching associated with the condition.

The study is observational, following a cohort model with a prospective time perspective. Participants are observed over a period of up to two years, with regular assessments conducted to monitor treatment outcomes.

The study began on December 27, 2023, with a primary completion date yet to be determined. The last update was submitted on August 12, 2025, indicating ongoing progress in the study.

This update could positively impact Sanofi’s stock performance by reinforcing investor confidence in the company’s commitment to addressing unmet medical needs. The study’s outcomes may also influence the competitive landscape in dermatological treatments.

The study is currently recruiting, with further details available on the ClinicalTrials portal.